Privia Health Group, Inc. (PRVA)
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
- Symbol
- PRVA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Health Information Services
- Market cap
- $2.46B
- 52 week range
- 18.98 - 28.82
Valuation
- Share price
- $19.10 (close of 2026-09-23)
- P/E (TTM)
- 84.61x
- Price to book
- 2.93x
- Price to free cash flow
- 18.74x
- Enterprise value
- $2.05B
- Book value per share
- $6.64
Price performance
| Period | Change |
|---|
| 1 day | -2.25% |
| 5 days | -6.19% |
| 1 month | -9.56% |
| 3 months | -19.55% |
| 6 months | -11.25% |
| Year to date | -19.44% |
| 1 year | -18.65% |
| 3 years | -11.70% |
| 5 years | -28.57% |
| All time | -16.96% |
Profitability and growth
- Return on equity
- 2.90%
- Return on invested capital
- 6.24%
- Return on assets
- 1.67%
- Return on capital employed
- 4.27%
- Gross margin
- 9.40%
- Net margin
- 1.08%
- EBITDA margin
- 2.08%
- Revenue growth
- 22.26%
- Net income growth
- 59.33%
- Free cash flow growth
- 49.53%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.34%
- Current ratio
- 1.62x
- Net debt to EBITDA
- -7.09x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $2.12B
- Cost of revenue
- $1.92B
- Gross profit
- $199.52M
- EBITDA
- $44.14M
- Net income
- $22.92M
- Earnings per share
- $0.19
- Shares outstanding
- 122.18M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $2.12B | $199.52M | $22.92M | $0.19 |
| 2024-12-31 | $1.74B | $169.59M | $14.38M | $0.12 |
| 2023-12-31 | $1.66B | $154.97M | $23.08M | $0.20 |
| 2022-12-31 | $1.36B | $130.21M | $-8.59M | $-0.08 |
| 2021-12-31 | $966.22M | $61.20M | $-188.23M | $-1.83 |
| 2020-12-31 | $817.08M | $80.74M | $31.24M | $0.33 |
| 2019-12-31 | $786.36M | $67.05M | $8.24M | $0.09 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 9.40% | 1.08% | 2.90% | 6.24% |
| 2024-12-31 | 9.77% | 0.83% | 2.10% | 4.29% |
| 2023-12-31 | 9.35% | 1.39% | 3.80% | 5.60% |
| 2022-12-31 | 9.60% | -0.63% | -1.65% | -6.91% |
| 2021-12-31 | 6.33% | -19.48% | -41.81% | -132.07% |
| 2020-12-31 | 9.88% | 3.82% | 21.75% | 43.00% |
| 2019-12-31 | 8.53% | 1.05% | 7.67% | 24.53% |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $479.69M |
| 2024-12-31 | $491.15M |
| 2023-12-31 | $389.51M |
| 2022-12-31 | $347.99M |
| 2021-12-31 | $320.58M |
| 2020-12-31 | $84.63M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $163.40M | $71.07M |
| 2024-12-31 | $109.28M | $56.68M |
| 2023-12-31 | $80.67M | $37.10M |
| 2022-12-31 | $47.09M | $67.36M |
| 2021-12-31 | $54.51M | $253.53M |
| 2020-12-31 | $38.51M | $484.00K |
| 2019-12-31 | $18.65M | $207.00K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $0.09
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.08 |
| 2026-05-07 | - | - |
| 2026-02-26 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-27 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- priviahealth.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades